hydroxyindoleacetic acid has been researched along with Neuroendocrine Tumors in 54 studies
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.
Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Excerpt | Relevance | Reference |
---|---|---|
"Urinary 5-hydroxyindoleacetic acid (5-HIAA) is an established biomarker in neuroendocrine tumors and carcinoid syndrome; however, its role in nonfunctional neuroendocrine tumors is not defined." | 9.30 | Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. ( Fisher, GA; Liyanage, N; Mirakhur, B; Pavel, ME; Phan, AT; Pitman Lowenthal, S; Vinik, AI; Wolin, EM, 2019) |
"Urinary 5-hydroxyindoleacetic acid (5-HIAA) is an established biomarker in neuroendocrine tumors and carcinoid syndrome; however, its role in nonfunctional neuroendocrine tumors is not defined." | 5.30 | Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. ( Fisher, GA; Liyanage, N; Mirakhur, B; Pavel, ME; Phan, AT; Pitman Lowenthal, S; Vinik, AI; Wolin, EM, 2019) |
"Serum 5-hydroxyindoleacetic acid (5-HIAA) could replace the determination of 24-h urinary 5-HIAA for diagnosis and follow-up of neuroendocrine tumors (NETs)." | 3.80 | Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker. ( Hämäläinen, E; Itkonen, O; Joenväärä, S; Markkanen, H; Renkonen, R; Sane, T; Tohmola, N, 2014) |
"5-Hydroxyindoleacetic acid (5-HIAA) is used for the evaluation of neuroendocrine tumors (NETs) but currently requires a 24-hour urine collection." | 3.79 | A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). ( Mamikunian, G; O'Dorisio, TM; Tellez, MR; Vinik, AI; Woltering, EA, 2013) |
"The urinary excretion of vanillylmandelic acid (VMA), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) can be increased in the presence of neuroblastic and carcinoid tumors." | 3.74 | HPLC-mass spectrometry method for quantitative detection of neuroendocrine tumor markers: vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid. ( Cardelli, P; Lionetto, L; Lostia, AM; Simmaco, M; Stigliano, A, 2008) |
"The predominant histotype was carcinoid, although a few cases had malignant islet cell tumors, medullary thyroid carcinoma, Merkel cell carcinoma, or other neuroendocrine tumors." | 2.67 | Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. ( Bajetta, E; Bochicchio, AM; Buzzoni, R; Castellani, R; Celio, L; Di Bartolomeo, M; Di Leo, A; Dogliotti, L; Pilotti, S; Zilembo, N, 1993) |
"Neuroendocrine tumors are increasingly diagnosed, either incidentally as part of screening processes, or for symptoms, which have commonly been mistaken for other disorders initially." | 2.53 | Neuroendocrine Tumors. ( Basuroy, R; Ramage, JK; Srirajaskanthan, R, 2016) |
"Primary ovarian carcinoid tumors are rare neuroendocrine tumors, and can be associated with carcinoid syndrome and carcinoid heart disease." | 1.72 | A Case of Primary Insular Ovarian Carcinoid Tumor with Hyperandrogenism and Carcinoid Heart Disease. ( Al-Agha, R; Anaka, MR; Mansour, S, 2022) |
"Direct-matrix derivatization in combination with LC-MS/MS is a powerful tool for the simultaneous quantification of all tryptophan-related indoles in platelet-rich plasma." | 1.51 | Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors. ( Bouma, G; de Hosson, LD; de Vries, EGE; Kats-Ugurlu, G; Kema, IP; Peters, MAM; van Faassen, M; Walenkamp, AME, 2019) |
"18 patients with metastatic carcinoids who underwent 111In-pentetreotide scanning were all somatostatin receptor positive." | 1.29 | Somatostatin receptor imaging: predictive and prognostic considerations. ( Anthony, LB; Delbeke, D; Martin, W; Sandler, M, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 8 (14.81) | 18.2507 |
2000's | 11 (20.37) | 29.6817 |
2010's | 29 (53.70) | 24.3611 |
2020's | 6 (11.11) | 2.80 |
Authors | Studies |
---|---|
Meyer, T | 1 |
Caplin, M | 2 |
Khan, MS | 1 |
Toumpanakis, C | 1 |
Shetty, S | 1 |
Ramage, JK | 2 |
Houchard, A | 1 |
Higgs, K | 1 |
Shah, T | 1 |
Kostiainen, I | 1 |
Karppinen, N | 1 |
Simonen, P | 1 |
Rosengård-Bärlund, M | 1 |
Lindén, R | 1 |
Tarkkanen, M | 1 |
Gordin, D | 1 |
Rapola, J | 1 |
Schalin-Jäntti, C | 2 |
Matikainen, N | 1 |
Mansour, S | 1 |
Anaka, MR | 1 |
Al-Agha, R | 1 |
van Faassen, M | 1 |
Bouma, G | 1 |
de Hosson, LD | 1 |
Peters, MAM | 1 |
Kats-Ugurlu, G | 1 |
de Vries, EGE | 1 |
Walenkamp, AME | 1 |
Kema, IP | 1 |
Gut, P | 1 |
Ruchała, M | 1 |
de Mestier, L | 1 |
Savagner, F | 1 |
Brixi, H | 1 |
Do Cao, C | 1 |
Dominguez-Tinajero, S | 1 |
Roquin, G | 1 |
Goichot, B | 1 |
Hentic, O | 1 |
Dubreuil, O | 1 |
Hautefeuille, V | 2 |
Walter, T | 2 |
Cadiot, G | 1 |
Maurel, J | 1 |
Guimbaud, R | 1 |
Lecomte, T | 1 |
Lièvre, A | 1 |
Robinson, P | 1 |
Francois, L | 1 |
Lombard-Bohas, C | 1 |
Forestier, J | 1 |
Milot, L | 2 |
Subtil, F | 1 |
Zandee, WT | 2 |
Brabander, T | 1 |
Blažević, A | 1 |
Minczeles, NS | 1 |
Feelders, RA | 2 |
de Herder, WW | 3 |
Hofland, J | 1 |
Rodríguez Laval, V | 1 |
Pavel, M | 1 |
Steffen, IG | 1 |
Baur, AD | 1 |
Dilz, LM | 1 |
Fischer, C | 1 |
Detjen, K | 1 |
Prasad, V | 1 |
Pascher, A | 1 |
Geisel, D | 1 |
Denecke, T | 1 |
Chan, DL | 2 |
Clarke, SJ | 1 |
Diakos, CI | 1 |
Roach, PJ | 1 |
Bailey, DL | 1 |
Singh, S | 3 |
Pavlakis, N | 1 |
Dixon, M | 1 |
Law, CHL | 1 |
Koujanian, S | 1 |
Beyfuss, KA | 1 |
Myrehaug, S | 1 |
Hallet, J | 1 |
Lindström, M | 1 |
Tohmola, N | 2 |
Renkonen, R | 2 |
Hämäläinen, E | 2 |
Itkonen, O | 2 |
Tirosh, A | 1 |
Nilubol, N | 2 |
Patel, D | 1 |
Kebebew, E | 2 |
Pavel, ME | 1 |
Phan, AT | 1 |
Wolin, EM | 1 |
Mirakhur, B | 1 |
Liyanage, N | 1 |
Pitman Lowenthal, S | 1 |
Fisher, GA | 1 |
Vinik, AI | 3 |
Pinto, MP | 1 |
Muñoz Medel, M | 1 |
Carrillo, D | 1 |
Retamal, IN | 1 |
Bravo, ML | 1 |
Valenzuela, Y | 1 |
Nervi, B | 1 |
Sánchez, C | 1 |
Galindo, H | 1 |
Ibañez, C | 1 |
Peña, J | 1 |
Balmaceda, C | 1 |
Madrid, J | 1 |
Briones, J | 1 |
Torres, J | 1 |
Nilo, F | 1 |
Guarda, FJ | 1 |
Quintana, JC | 1 |
Orellana, P | 1 |
Mondaca, S | 1 |
Acevedo, F | 1 |
Vicentini, D | 1 |
Cordova-Delgado, M | 1 |
Owen, GI | 1 |
Garrido, M | 1 |
Padelli, M | 1 |
Bruno, C | 1 |
Lemarchand, J | 1 |
Vourc'h, P | 1 |
Andres, C | 1 |
Blasco, H | 1 |
Benz-de Bretagne, I | 1 |
Walsh, JS | 1 |
Newell-Price, JD | 1 |
DeBono, M | 1 |
Adaway, J | 1 |
Keevil, B | 2 |
Eastell, R | 1 |
Sen Gupta, P | 1 |
Grozinsky-Glasberg, S | 1 |
Drake, WM | 1 |
Akker, SA | 1 |
Perry, L | 1 |
Grossman, AB | 1 |
Druce, MR | 1 |
Sane, T | 1 |
Markkanen, H | 1 |
Joenväärä, S | 1 |
Dobson, R | 1 |
Cuthbertson, DJ | 1 |
Jones, J | 1 |
Valle, JW | 1 |
Chadwick, C | 1 |
Poston, GP | 1 |
Burgess, MI | 1 |
Nadler, A | 1 |
Cukier, M | 1 |
Law, CH | 1 |
Tőke, J | 1 |
Czirják, G | 1 |
Tóth, M | 1 |
Rácz, K | 1 |
Patócs, A | 1 |
Al-Efraij, K | 1 |
Aljama, MA | 1 |
Kennecke, HF | 1 |
Ardill, JE | 1 |
Armstrong, L | 1 |
Smye, M | 1 |
Doherty, R | 1 |
McCance, DR | 1 |
Johnston, BT | 1 |
Sadowski, SM | 1 |
Neychev, V | 1 |
Millo, C | 1 |
Shih, J | 1 |
Herscovitch, P | 1 |
Pacak, K | 1 |
Marx, SJ | 1 |
Jahagirdar, V | 1 |
Kamal, A | 1 |
Steeds, R | 1 |
Ayuk, J | 1 |
Kinová, S | 1 |
Kovácová, M | 1 |
Caprnda, M | 1 |
Koren, M | 1 |
Kamp, K | 1 |
van Adrichem, RC | 1 |
Basuroy, R | 1 |
Srirajaskanthan, R | 1 |
Lionetto, L | 1 |
Lostia, AM | 1 |
Stigliano, A | 1 |
Cardelli, P | 1 |
Simmaco, M | 1 |
Korse, CM | 1 |
Bonfrer, JM | 1 |
Aaronson, NK | 1 |
Hart, AA | 1 |
Taal, BG | 1 |
O'Toole, D | 1 |
Grossman, A | 1 |
Gross, D | 1 |
Delle Fave, G | 1 |
Barkmanova, J | 1 |
O'Connor, J | 1 |
Pape, UF | 1 |
Plöckinger, U | 1 |
Manickum, T | 1 |
Berković, MC | 1 |
Jokić, M | 1 |
Marout, J | 1 |
Radosević, S | 1 |
Zjacić-Rotkvić, V | 1 |
Kapitanović, S | 1 |
Woltering, EA | 2 |
Warner, RR | 1 |
O'Dorisio, TM | 2 |
Wiseman, GA | 1 |
Coppola, D | 1 |
Go, VL | 1 |
Figueroa-Vega, N | 1 |
Díaz, A | 1 |
Adrados, M | 1 |
Alvarez-Escolá, C | 1 |
Paniagua, A | 1 |
Aragonés, J | 1 |
Martín-Pérez, E | 1 |
Leskela, S | 1 |
Moreno-Otero, R | 1 |
González-Amaro, R | 1 |
Marazuela, M | 1 |
Gregersen, T | 1 |
Grønbæk, H | 1 |
Worsøe, J | 1 |
Schlageter, V | 1 |
Laurberg, S | 1 |
Krogh, K | 1 |
Tellez, MR | 1 |
Mamikunian, G | 1 |
Monteleone, M | 1 |
Naccarato, A | 1 |
Sindona, G | 1 |
Tagarelli, A | 1 |
Piette, C | 1 |
Polus, M | 1 |
Louis, E | 1 |
De Block, CE | 1 |
Colpin, G | 1 |
Thielemans, K | 1 |
Coopmans, W | 2 |
Bogers, JJ | 1 |
Pelckmans, PA | 1 |
Van Marck, EA | 1 |
Van Hoof, V | 1 |
Martin, M | 1 |
De Leeuw, IH | 1 |
Bouillon, R | 2 |
Van Gaal, LF | 1 |
Søndenaa, K | 1 |
Sen, J | 1 |
Heinle, F | 1 |
Fjetland, L | 1 |
Gudlaugsson, E | 1 |
Syversen, U | 1 |
Rorstad, O | 1 |
Ferolla, P | 1 |
Faggiano, A | 1 |
Mansueto, G | 1 |
Avenia, N | 1 |
Cantelmi, MG | 1 |
Giovenali, P | 1 |
Del Basso De Caro, ML | 1 |
Milone, F | 1 |
Scarpelli, G | 1 |
Masone, S | 1 |
Santeusanio, F | 1 |
Lombardi, G | 1 |
Angeletti, G | 1 |
Colao, A | 1 |
Nold, R | 1 |
Frank, M | 1 |
Kajdan, U | 1 |
Trost, U | 1 |
Klose, KJ | 1 |
Arnold, R | 1 |
Jacobsen, MB | 1 |
Hanssen, LE | 1 |
Bajetta, E | 2 |
Zilembo, N | 2 |
Di Bartolomeo, M | 2 |
Di Leo, A | 1 |
Pilotti, S | 1 |
Bochicchio, AM | 1 |
Castellani, R | 1 |
Buzzoni, R | 1 |
Celio, L | 2 |
Dogliotti, L | 1 |
Anthony, LB | 1 |
Martin, W | 1 |
Delbeke, D | 1 |
Sandler, M | 1 |
Nobels, FR | 1 |
Kwekkeboom, DJ | 1 |
Schoenmakers, CH | 1 |
Lindemans, J | 1 |
Krenning, EP | 1 |
Lamberts, SW | 1 |
Baudin, E | 1 |
Bidart, JM | 1 |
Rougier, P | 1 |
Lazar, V | 1 |
Ruffié, P | 1 |
Ropers, J | 1 |
Ducreux, M | 1 |
Troalen, F | 1 |
Sabourin, JC | 1 |
Comoy, E | 1 |
Lasser, P | 1 |
DeBaere, T | 1 |
Schlumberger, M | 1 |
Brannan, SO | 1 |
Lessan, NG | 1 |
Hiscott, P | 1 |
Damato, B | 1 |
Ferrari, L | 1 |
Martinetti, A | 1 |
Procopio, G | 1 |
Artale, S | 1 |
Seregni, E | 1 |
Bombardieri, E | 1 |
Eriksson, B | 1 |
Oberg, K | 1 |
Stridsberg, M | 1 |
Ricci, S | 1 |
Antonuzzo, A | 1 |
Galli, L | 1 |
Ferdeghini, M | 1 |
Bodei, L | 1 |
Orlandini, C | 1 |
Conte, PF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase IV, Multicentre, Open Label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients Receiving Deep Subcutaneo[NCT02075606] | Phase 4 | 50 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors[NCT02826928] | 116 participants (Actual) | Interventional | 2016-10-26 | Completed | |||
Overall Survival and Progression Free Survival of Patients With Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV[NCT03998332] | 132 participants (Actual) | Observational | 2002-01-01 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Subjects underwent CT or MRI scans at baseline and Week 53. Progression was assessed by investigators using RECIST v1.1. The best overall response to study treatment is the highest time point response achieved by the subject and was assessed as a complete response, partial response, stable disease, progressive disease or non evaluable. For analysis of PFS, event dates were assigned to the first time that progressive disease was noted or the date of death. In case of progressive disease followed by death, the first event was considered in the analysis. Censoring dates were defined in subjects with no progressive disease or death before end of study.~At one year (end of study), the mean percentage of subjects who were alive and progression free, as calculated using the Kaplan-Meier method, is reported by CTC presence and overall." (NCT02075606)
Timeframe: From baseline up to Week 53.
Intervention | percentage of subjects (Mean) |
---|---|
CTC Presence at Baseline | 69.00 |
No CTC Presence at Baseline | 67.75 |
Lanreotide Autogel | 66.43 |
"This endpoint was assessed using 2 efficacy variables:~CTCs, enumerated at baseline and Weeks 5, 17, 25, 53~Clinical symptomatic response, assessed by the use of symptom reporting~Subjects recorded 24-hour symptom frequency and severity for 7 days prior to first treatment (baseline), throughout the study, and up to 28 days following final drug administration. Symptoms were recorded by answering predetermined questions on the interactive voice response system (IVRS).~Subjects were considered to have a clinical symptomatic response between baseline and last study visit if any 1 of the following criteria were fulfilled: the average number of episodes of diarrhoea decreased by at least 50%, the average number of episodes of flushing decreased by at least 50%, the mode severity of flushing decreased by at least 1 level. Clinical symptomatic response was assessed as a qualitative variable (Yes/No) and reported according to CTC presence at baseline and overall." (NCT02075606)
Timeframe: From baseline up to Week 53.
Intervention | Percentage of Subjects (Number) | |
---|---|---|
Clinical Symptomatic Response = Yes(2) | Clinical Symptomatic Response = No(3) | |
CTC Presence at Baseline | 77.8 | 22.2 |
Lanreotide Autogel | 87.5 | 12.5 |
No CTC Presence at Baseline | 95.5 | 4.5 |
"The effect of lanreotide Autogel on the symptoms of diarrhoea and flushing in subjects was assessed through subject reporting of symptoms every 24-hours for the 7 days prior to treatment (baseline), for the first 16 weeks and on days 11 to 17 after each subsequent injection interval. After the final study drug injection at Week 49, subjects provided 24-hour symptom frequency on days 11 to 28 (up to Week 53). Symptom frequency was recorded by answering predetermined questions on the IVRS.~Mean change from baseline in frequency (number of episodes) of diarrhoea and flushing are described at Visit 2 (average number of episodes in Week 1) and at Visit 14 (average number of episodes over days 11 to 17 after Week 49 injection and over days 11 to 28 after Week 49 injection) by CTC presence at baseline and overall. A negative change indicates an improvement in symptoms from baseline." (NCT02075606)
Timeframe: From baseline up to Week 53.
Intervention | number of episodes (Mean) | |
---|---|---|
Diarrhoea: Visit 2 (daily) | Flushing: Visit 2 (daily) | |
Missing CTC Status at Baseline | 0.38 | 0.00 |
"The effect of lanreotide Autogel on the symptoms of diarrhoea and flushing in subjects was assessed through subject reporting of symptoms every 24-hours for the 7 days prior to treatment (baseline), for the first 16 weeks and on days 11 to 17 after each subsequent injection interval. After the final study drug injection at Week 49, subjects provided 24-hour symptom frequency on days 11 to 28 (up to Week 53). Symptom frequency was recorded by answering predetermined questions on the IVRS.~Mean change from baseline in frequency (number of episodes) of diarrhoea and flushing are described at Visit 2 (average number of episodes in Week 1) and at Visit 14 (average number of episodes over days 11 to 17 after Week 49 injection and over days 11 to 28 after Week 49 injection) by CTC presence at baseline and overall. A negative change indicates an improvement in symptoms from baseline." (NCT02075606)
Timeframe: From baseline up to Week 53.
Intervention | number of episodes (Mean) | |||||
---|---|---|---|---|---|---|
Diarrhoea: Visit 2 (daily) | Diarrhoea: Visit 14 (days 11-17) | Diarrhoea: Visit 14 (days 11-28) | Flushing: Visit 2 (daily) | Flushing: Visit 14 (days 11-17) | Flushing: Visit 14 (days 11-28) | |
CTC Presence at Baseline | -0.66 | -1.91 | -2.15 | -1.76 | -3.37 | -3.49 |
Lanreotide Autogel | -0.42 | -1.18 | -1.30 | -1.43 | -2.88 | -2.79 |
No CTC Presence at Baseline | -0.27 | -0.64 | -0.63 | -1.25 | -2.51 | -2.23 |
The effect of lanreotide Autogel on the mode severity of flushing was assessed through subject reporting of symptoms every 24-hours for the 7 days prior to treatment (baseline), for the first 16 weeks and on days 11 to 17 after each subsequent injection interval until Week 49. After the final study drug injection at Week 49, subjects provided 24-hour symptom severity on days 11 to 28 (up to Week 53). Symptom severity was recorded by answering predetermined questions on the IVRS using a three-point system (mild, moderate or severe). The mode (most frequent) intensity of flushing are reported at baseline and at Visit 14 (average number of episodes over days 11 to 17 after Week 49 injection and over days 11 to 28 after Week 49 injection). Percentages of subjects in each severity category are based on the number of subjects in the analysis set with available responses. Data is presented according to CTC presence at baseline and overall. (NCT02075606)
Timeframe: From baseline up to Week 53.
Intervention | percentage of subjects (Number) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No flushing: Baseline | Mild: Baseline | Moderate: Baseline | Severe: Baseline | No flushing: Visit 14 (days 11-17) | Mild: Visit 14 (days 11-17) | Moderate: Visit 14 (days 11-17) | Severe: Visit 14 (days 11-17) | No flushing: Visit 14 (days 11-28) | Mild: Visit 14 (days 11-28) | Moderate: Visit 14 (days 11-28) | Severe: Visit 14 (days 11-28) | |
CTC Presence at Baseline | 22.7 | 27.3 | 45.5 | 4.5 | 37.5 | 43.8 | 18.8 | 0.0 | 13.3 | 60.0 | 26.7 | 0.0 |
Lanreotide Autogel | 14.0 | 38.0 | 46.0 | 2.0 | 32.4 | 45.9 | 21.6 | 0.0 | 23.5 | 55.9 | 17.6 | 2.9 |
No CTC Presence at Baseline | 0.0 | 50.0 | 50.0 | 0.0 | 28.6 | 47.6 | 23.8 | 0.0 | 31.6 | 52.6 | 10.5 | 5.3 |
The effect of lanreotide Autogel on the mode severity of flushing was assessed through subject reporting of symptoms every 24-hours for the 7 days prior to treatment (baseline), for the first 16 weeks and on days 11 to 17 after each subsequent injection interval until Week 49. After the final study drug injection at Week 49, subjects provided 24-hour symptom severity on days 11 to 28 (up to Week 53). Symptom severity was recorded by answering predetermined questions on the IVRS using a three-point system (mild, moderate or severe). The mode (most frequent) intensity of flushing are reported at baseline and at Visit 14 (average number of episodes over days 11 to 17 after Week 49 injection and over days 11 to 28 after Week 49 injection). Percentages of subjects in each severity category are based on the number of subjects in the analysis set with available responses. Data is presented according to CTC presence at baseline and overall. (NCT02075606)
Timeframe: From baseline up to Week 53.
Intervention | percentage of subjects (Number) | |||
---|---|---|---|---|
No flushing: Baseline | Mild: Baseline | Moderate: Baseline | Severe: Baseline | |
Missing CTC Status at Baseline | 100 | 0.0 | 0.0 | 0.0 |
"Subjects underwent Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scans at baseline, Visit 8 (Week 25) and Visit 15 (Week 53). Progression was assessed by investigators using RECIST v1.1, and classified as a complete response, partial response, stable disease, progressive disease or non evaluable.~The time point responses at Week 25 and Week 53 were analysed by CTC presence at baseline and overall. The percentage of subjects within each response category are presented. Percentages are based on the number of subjects in the concerned population with available responses." (NCT02075606)
Timeframe: Week 25 and Week 53.
Intervention | percentage of subjects (Number) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Week 25: Complete Response | Week 25: Partial Response | Week 25: Stable Disease | Week 25: Progressive Disease | Week 25: Non evaluable | Week 53: Complete Response | Week 53: Partial Response | Week 53: Stable Disease | Week 53: Progressive Disease | Week 53: Non evaluable | |
CTC Presence at Baseline | 0.0 | 18.2 | 72.7 | 9.1 | 0.0 | 0.0 | 6.7 | 66.7 | 26.7 | 0.0 |
Lanreotide Autogel | 0.0 | 13.0 | 73.9 | 13.0 | 0.0 | 0.0 | 5.4 | 64.9 | 29.7 | 0.0 |
No CTC Presence at Baseline | 0.0 | 8.3 | 75.0 | 16.7 | 0.0 | 0.0 | 4.5 | 63.6 | 31.8 | 0.0 |
The effect of lanreotide Autogel treatment on QoL was assessed using the EORTC QLQ-G.I.NET21 at baseline, Weeks 13 (Visit 5), 25 (Visit 8) and 53 (Visit 15/end of study). The QLQ-G.I.NET21 questionnaire contained 21 questions that used a 4-point scale (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much) to evaluate 3 defined multi-item symptom scales (endocrine, gastrointestinal and treatment related side effects), 2 single item symptoms (bone/muscle pain and concern about weight loss), 2 psychosocial scales (social function and disease-related worries) and 2 other single items (sexuality and communication). Each individual subscore was transformed to range from 0 to 100. Higher scores indicate worse symptoms or more problems. The mean change from baseline at each time point is reported for each of the category subscores. (NCT02075606)
Timeframe: From baseline up to Week 53.
Intervention | Units on a scale (Mean) | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endocrine symptoms: Visit 5 | Endocrine symptoms: Visit 8 | Endocrine symptoms: End of study | Gastrointestinal symptoms: Visit 5 | Gastrointestinal symptoms: Visit 8 | Gastrointestinal symptoms: End of study | Treatment symptoms: Visit 5 | Treatment symptoms: Visit 8 | Treatment symptoms: End of study | Social function: Visit 5 | Social function: Visit 8 | Social function: End of study | Disease related worries: Visit 5 | Disease related worries: Visit 8 | Disease related worries: End of study | Muscle/Bone pain: Visit 5 | Muscle/Bone pain: Visit 8 | Muscle/Bone pain: End of study | Sexual function: Visit 5 | Sexual function: Visit 8 | Sexual function: End of study | Information/communication function: Visit 5 | Information/communication function: Visit 8 | Information/communication function: End of study | Body image: Visit 5 | Body image: Visit 8 | Body image: End of study | |
Lanreotide Autogel | -15.4 | -17.0 | -16.0 | 2.1 | 1.2 | 1.0 | 1.2 | 7.6 | 12.0 | -11.3 | -6.5 | -4.5 | -14.1 | -15.9 | -12.2 | -7.9 | -6.5 | -11.8 | -5.6 | -8.9 | -13.3 | -8.5 | -3.7 | -5.6 | 0.9 | 1.9 | -1.0 |
"The effect of lanreotide Autogel treatment on QoL was assessed using the EORTC QLQ-C30 at baseline, Weeks 13 (Visit 5), 25 (Visit 8) and 53 (Visit 15/end of study). The 30 item scale is divided into 9 multi item scales (including 5 functional scales, 1 global health status/QoL scale and 3 general symptom scales) and 6 single items. Possible answers to the first 28 items (all items except the 2 concerning global quality of life) go from 1 (Not at all) to 4 (Very much). The answers for the 2 last questions (Q29- 30) go from 1 (Very poor) to 7 (Excellent). All of the scales and single-item measures range in score from 0 to 100. For multi-item scales, the raw score will be calculated by the addition of item responses divided by the number of items. Higher scores for global health and functional domains indicate a better QoL, while higher symptom scores indicate worse symptoms.~The mean change from baseline at each time point is reported for each of the category subscores." (NCT02075606)
Timeframe: From baseline up to Week 53.
Intervention | Units on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Physical functioning: Visit 5 | Physical functioning: Visit 8 | Physical functioning: End of study | Role functioning: Visit 5 | Role functioning: Visit 8 | Role functioning: End of study | Emotional functioning: Visit 5 | Emotional functioning: Visit 8 | Emotional functioning: End of study | Cognitive functioning: Visit 5 | Cognitive functioning: Visit 8 | Cognitive functioning: End of study | Social functioning: Visit 5 | Social functioning: Visit 8 | Social functioning: End of study | Global QoL: Visit 5 | Global QoL: Visit 8 | Global QoL: End of study | Fatigue: Visit 5 | Fatigue: Visit 8 | Fatigue: End of study | Nausea and vomiting: Visit 5 | Nausea and vomiting: Visit 8 | Nausea and vomiting: End of study | Pain: Visit 5 | Pain: Visit 8 | Pain: End of study | Dyspnoea: Visit 5 | Dyspnoea: Visit 8 | Dyspnoea: End of study | Insomnia: Visit 5 | Insomnia: Visit 8 | Insomnia: End of study | Appetite loss: Visit 5 | Appetite loss: Visit 8 | Appetite loss: End of study | Constipation: Visit 5 | Constipation: Visit 8 | Constipation: End of study | Diarrhoea: Visit 5 | Diarrhoea: Visit 8 | Diarrhoea: End of study | Financial difficulties: Visit 5 | Financial difficulties: Visit 8 | Financial difficulties: End of study | |
Lanreotide Autogel | 1.2 | 2.0 | 1.9 | 1.3 | 3.2 | -1.4 | 6.1 | 4.3 | 1.1 | -0.9 | 1.5 | -2.4 | 10.0 | 4.5 | 3.9 | 12.5 | 7.4 | 4.3 | -4.4 | -6.3 | -4.2 | -4.2 | -1.4 | -0.9 | -7.9 | -2.3 | 1.8 | -3.5 | 1.0 | -4.8 | -6.3 | -5.7 | -2.9 | -0.9 | -6.5 | -0.0 | 1.9 | -1.0 | 1.9 | -18.5 | -12.7 | -10.8 | -6.7 | -4.0 | -1.0 |
7 reviews available for hydroxyindoleacetic acid and Neuroendocrine Tumors
Article | Year |
---|---|
Prognostic and predictive biomarkers in neuroendocrine tumours.
Topics: Biomarkers, Tumor; Chromogranin A; Epigenesis, Genetic; Humans; Hydroxyindoleacetic Acid; Ki-67 Anti | 2017 |
[Significance of biochemical markers in the diagnosis of neuroendocrine tumours and for the follow-up of patients].
Topics: 5-Hydroxytryptophan; Biomarkers, Tumor; Chorionic Gonadotropin; Chromogranins; Glucagon; Humans; Hyd | 2014 |
Neuroendocrine Tumors.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Chromogranin A; Digestive System Surgical Pr | 2016 |
[Pathological implications in the neuroendocrine gastrointestinal system].
Topics: Carcinoid Tumor; Combined Modality Therapy; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic | 2002 |
Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.
Topics: Biomarkers, Tumor; Carcinoid Heart Disease; Carcinoid Tumor; Chromogranin A; Chromogranins; Gastroin | 2005 |
The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers.
Topics: Biomarkers; Biomarkers, Tumor; Chromogranin A; Genetic Markers; Humans; Hydroxyindoleacetic Acid; Ne | 2008 |
Tumor markers in neuroendocrine tumors.
Topics: Biomarkers, Tumor; Chromogranins; Humans; Hydroxyindoleacetic Acid; Immunohistochemistry; Neuroendoc | 2000 |
6 trials available for hydroxyindoleacetic acid and Neuroendocrine Tumors
Article | Year |
---|---|
Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours.
Topics: Adult; Biomarkers, Tumor; Disease Progression; Humans; Hydroxyindoleacetic Acid; Neoplastic Cells, C | 2022 |
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chromogranin A; Female; Fo | 2019 |
Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cecum; Chromogra | 2011 |
Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial.
Topics: Adaptation, Psychological; Adult; Aged; Biomarkers, Tumor; Double-Blind Method; Female; Gastrointest | 1995 |
Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoid Tumor; Drug Administration Schedule; Female; Fever; Humans | 1993 |
Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoid Tumor; | 2000 |
41 other studies available for hydroxyindoleacetic acid and Neuroendocrine Tumors
Article | Year |
---|---|
Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
Topics: Biomarkers; Carcinoid Heart Disease; Carcinoid Tumor; Cross-Sectional Studies; Humans; Hydroxyindole | 2022 |
A Case of Primary Insular Ovarian Carcinoid Tumor with Hyperandrogenism and Carcinoid Heart Disease.
Topics: Adult; Carcinoid Heart Disease; Carcinoid Tumor; Chromogranin A; Chromogranins; Female; Humans; Hydr | 2022 |
Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors.
Topics: 5-Hydroxytryptophan; Adult; Aged; Biomarkers, Tumor; Chromatography, Liquid; Female; Humans; Hydroxy | 2019 |
Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues.
Topics: Aged; Antineoplastic Agents, Hormonal; Female; Humans; Hydroxyindoleacetic Acid; Intestinal Neoplasm | 2019 |
Plasmatic and Urinary 5-Hydroxyindolacetic Acid Measurements in Patients With Midgut Neuroendocrine Tumors: A GTE Study.
Topics: Aged; Biomarkers, Tumor; Female; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic Acid; Male; | 2021 |
Value of a patient-reported-outcome measure of carcinoid syndrome symptoms.
Topics: Aged; Cohort Studies; Female; Food; France; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcin | 2021 |
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diarrhea; Drug Resistance, Neoplasm; Female; Humans; Hydrox | 2021 |
Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features.
Topics: Aged; Cohort Studies; Female; Fibrosis; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic Acid | 2018 |
Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
Topics: Aged; Cytoreduction Surgical Procedures; Embolization, Therapeutic; Female; Hepatectomy; Humans; Hyd | 2018 |
Comparison of serum serotonin and serum 5-HIAA LC-MS/MS assays in the diagnosis of serotonin producing neuroendocrine neoplasms: A pilot study.
Topics: Chromatography, Liquid; Humans; Hydroxyindoleacetic Acid; Neuroendocrine Tumors; Pilot Projects; Ref | 2018 |
Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.
Topics: Adult; Aged; Disease Progression; Female; Humans; Hydroxyindoleacetic Acid; Intestinal Neoplasms; In | 2018 |
Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective.
Topics: Adult; Aged; Aged, 80 and over; Chile; Chromogranin A; Female; Humans; Hydroxyindoleacetic Acid; Inc | 2019 |
[Determination of thresholds values for platelet serotonin and urinary 5-HIAA concentrations for the biological diagnosis of digestive neuroendocrine tumors].
Topics: Adult; Aged; Biomarkers; Blood Chemical Analysis; Blood Platelets; Cohort Studies; Digestive System | 2019 |
Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome.
Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Case-Contro | 2013 |
Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
Topics: Absorptiometry, Photon; Aged; Bone Density; Female; Humans; Hydroxyindoleacetic Acid; Linear Models; | 2014 |
Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Female; Humans; Hydroxyindoleacetic Acid; Male; Mass Spe | 2014 |
Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease.
Topics: Aged; Aged, 80 and over; Biomarkers; Carcinoid Heart Disease; Echocardiography; Feasibility Studies; | 2014 |
Hepatic parenchymal preserving technique in the management of diffuse bilateral neuroendocrine tumour liver metastases: a feasible approach.
Topics: Adult; Aged; Chromogranin A; Feasibility Studies; Female; Hepatectomy; Humans; Hydroxyindoleacetic A | 2014 |
Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Chromogranin A; | 2015 |
Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Topics: Adult; Biomarkers, Tumor; Chromogranin A; Diagnosis, Differential; Female; Humans; Hydroxyindoleacet | 2016 |
Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Topics: Adult; Aged; Aged, 80 and over; Chromogranin A; Female; Humans; Hydroxyindoleacetic Acid; Intestinal | 2016 |
Metastatic small bowel neuroendocrine tumour with bilateral carcinoid heart disease.
Topics: Carcinoid Heart Disease; Chromogranin A; Endocarditis; Fatal Outcome; Female; Humans; Hydroxyindolea | 2016 |
[Management of treatment in patients with neuroendocrine neoplasmas of digestive tract].
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Chromogranin A; Endoscopy, Digestive System; Female | 2015 |
Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
Topics: Aged; Biomarkers, Tumor; Female; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic Acid; Male; | 2016 |
HPLC-mass spectrometry method for quantitative detection of neuroendocrine tumor markers: vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid.
Topics: Biomarkers, Tumor; Calibration; Carcinoid Tumor; Chromatography, High Pressure Liquid; Homovanillic | 2008 |
Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoid Tumor; Chromogranin A; Female; Follow-U | 2009 |
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers.
Topics: Biomarkers; Chromogranin A; Fasting; Gastrinoma; Humans; Hydroxyindoleacetic Acid; Hypoglycemia; Ins | 2009 |
Simultaneous analysis of neuroendocrine tumor markers by HPLC-electrochemical detection.
Topics: Adrenal Gland Neoplasms; Adult; Biomarkers, Tumor; Child; Child, Preschool; Chromatography, High Pre | 2009 |
IL-2 -330 T/G SNP and serum values-potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (GEP-NETs).
Topics: Adult; Aged; Alleles; Biomarkers, Tumor; Cytokines; Female; Gastrointestinal Neoplasms; Genetic Pred | 2010 |
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor.
Topics: Biomarkers, Tumor; Chromogranin A; Humans; Hydroxyindoleacetic Acid; Neuroendocrine Tumors | 2010 |
The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors.
Topics: Angiopoietin-1; Angiopoietin-2; Chemotaxis; Chromogranin A; Digestive System Neoplasms; Female; Flow | 2010 |
A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Chromogranin A; Disease Progression; Fasting; Female; Ga | 2013 |
A reliable and simple method for the assay of neuroendocrine tumor markers in human urine by solid-phase microextraction-gas chromatography-triple quadrupole mass spectrometry.
Topics: Adult; Biomarkers, Tumor; Female; Gas Chromatography-Mass Spectrometry; Homovanillic Acid; Humans; H | 2013 |
Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes.
Topics: Autoantibodies; Biomarkers, Tumor; Chromogranin A; Chromogranins; Diabetes Mellitus, Type 1; Enteroc | 2004 |
Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report.
Topics: Adult; Aged; Aged, 80 and over; Chromogranin A; Chromogranins; Female; Humans; Hydroxyindoleacetic A | 2004 |
[Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha].
Topics: Biomarkers, Tumor; Combined Modality Therapy; Female; Gastrinoma; Gastrins; Gastrointestinal Neoplas | 1994 |
Somatostatin receptor imaging: predictive and prognostic considerations.
Topics: Carcinoid Tumor; Female; Hormone Antagonists; Humans; Hydroxyindoleacetic Acid; Indium Radioisotopes | 1996 |
Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoid Tumor; Carcinoma, Medullary; Carcinoma, Small Cell; Chromo | 1997 |
Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors.
Topics: Adult; Aged; Calcitonin; Chorionic Gonadotropin, beta Subunit, Human; Female; Hormones; Humans; Hydr | 1999 |
A choroidal amyloid-rich neuroendocrine tumor: initial manifestation of Cushing syndrome.
Topics: Amyloidosis; Choroid Neoplasms; Cushing Syndrome; Humans; Hydroxyindoleacetic Acid; Male; Middle Age | 1999 |
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
Topics: Biomarkers; Carcinoembryonic Antigen; Chromogranin A; Chromogranins; Female; Humans; Hydroxyindoleac | 1999 |